Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HST Global and Ebitda Capital form strategic alliance
Ron Howell, CEO and president of HST Global retained Ebitda Capital, said: “Through the use of the Ebitda Capital resources we at HST Global can focus on the
Ron Howell, CEO and president of HST Global retained Ebitda Capital, said: “Through the use of the Ebitda Capital resources we at HST Global can focus on the
Neurologix and Diamyd have signed the license agreement in August 2006. It is a running agreement with milestone payments and royalty on sales. Elisabeth Lindner, president and CEO
ImmunoVEX HSV2 is a novel live-attenuated vaccine which has been rationally designed to remove the genes that allow herpes virus to avoid the immune system. This should allow
The trial is a double-blind, placebo-controlled, dose-escalating clinical study evaluating the safety and efficacy of the company’s topical drug candidate, RGN-137, in 72 patients with pressure ulcers who
Under the merger agreement, Lilly will acquire all of the outstanding shares of SGX common stock at a price of $3 per share. All other closing conditions have
In a two-part financing, Aposense raised $6 million in September 2007 and now concluded the second part of additional $7.3 million. A prominent group of existing shareholders participated
By delivering clinical data from over 60 different devices and over 30 vendors across 10 different modalities such as cardiograph, Holter, stress, patient monitoring, PFT, and defibrillator, CardioECG
Under the agreements, Noven has granted Procter & Gamble Pharmaceuticals (P&GP) an exclusive worldwide license to a testosterone patch for the treatment of hypoactive sexual desire disorder (HSDD)
Rosetta Genomics has access to the majority of known human and viral microRNAs. From this strong intellectual property position, the company has developed highly sensitive, proprietary technologies to
Mr Conn has served as a financial executive in high growth companies for over 20 years. Mr Conn has extensive experience with mergers and acquisitions and capital transactions.